Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05405491 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation

Study acronym: RESPIRE
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment reopened
    • Site details revised
    v5
  2. Primary and study completion dates: Sep 2024 to Mar 2028
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 160 to confirmed 31
    • Site details revised
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2023 to Mar 28, 2023
    v3
  4. Start date: Sep 2022 to Mar 2023v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RESPIRE is a randomized, unblinded, controlled study to measure the impact of a strategy based on a PCR test on the adjustment of antimicrobial therapy in immunocompromised patients suspected with ventilator-associated or hospital-acquired pneumonia (VAP/HAP) requiring mechanical ventilation (MV) in Intensive Care Unit (ICU). The gold-standard microbiological diagnostic method for pneumonia in the ICU is based on culture identification and antimicrobial susceptibility testing. Results are obtained in several days after the initiation of empiric antimicrobial therapy, exposing patients to a potential inappropriate broad-spectrum antimicrobial treatment. We aim to measure the impact of a PCR-based strategy to improve the percentage of patients with VAP or HAP receiving targeted antimicrobial therapy 24 hours after diagnosis compared to standard care
Trial Details
NCT Number NCT05405491
Lead Sponsor University Hospital, Lille
Conditions
(from sponsor)		 Pneumonia, Ventilator-Associated, Pneumonia, Hospital-Acquired, Immunodeficiency
Related terms Healthcare-Associated Pneumonia, Immunologic Deficiency Syndromes, Pneumonia, Ventilator-Associated
Enrollment 31 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov